1 / 23

Highlights of the Day:<br />Central Nervous System Tumors

Highlights of the Day:<br />Central Nervous System Tumors. Presented By Michael Prados at 2014 ASCO Annual Meeting. Slide 2. Presented By Michael Prados at 2014 ASCO Annual Meeting. R9802 SCHEMA. Presented By Michael Prados at 2014 ASCO Annual Meeting. Data Maturity.

carver
Download Presentation

Highlights of the Day:<br />Central Nervous System Tumors

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Highlights of the Day:<br />Central Nervous System Tumors Presented By Michael Prados at 2014 ASCO Annual Meeting

  2. Slide 2 Presented By Michael Prados at 2014 ASCO Annual Meeting

  3. R9802 SCHEMA Presented By Michael Prados at 2014 ASCO Annual Meeting

  4. Data Maturity Presented By Michael Prados at 2014 ASCO Annual Meeting

  5. Progression-Free Survival<br />ASCO 2014 Presented By Michael Prados at 2014 ASCO Annual Meeting

  6. Overall Survival<br />ASCO 2014 Presented By Michael Prados at 2014 ASCO Annual Meeting

  7. ASCO 2014: Overall Survival Presented By Michael Prados at 2014 ASCO Annual Meeting

  8. Cox Proportional Hazards Model for Overall Survival <br />(n=251) Presented By Michael Prados at 2014 ASCO Annual Meeting

  9. Conclusions (Prognostic Variables) Presented By Michael Prados at 2014 ASCO Annual Meeting

  10. Conclusions (Survival)<br /> Presented By Michael Prados at 2014 ASCO Annual Meeting

  11. Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779)/RT followed by CCI-779 versus chemo-irradiation with temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II study. Presented By Michael Prados at 2014 ASCO Annual Meeting

  12. EORTC 26082/22081: Study Design Presented By Michael Prados at 2014 ASCO Annual Meeting

  13. EORTC 26082/22081: Overall survival Presented By Michael Prados at 2014 ASCO Annual Meeting

  14. Conclusions Presented By Michael Prados at 2014 ASCO Annual Meeting

  15. Correlation of Molecular Subtypes <br />with Survival in AVAglio Presented By Michael Prados at 2014 ASCO Annual Meeting

  16. Introduction Presented By Michael Prados at 2014 ASCO Annual Meeting

  17. AVAglio Trial Design and Primary Endpoints Presented By Michael Prados at 2014 ASCO Annual Meeting

  18. ITT and Biomarker-Evaluable Populations Presented By Michael Prados at 2014 ASCO Annual Meeting

  19. Background: Glioblastoma Gene Expression Subtypes Presented By Michael Prados at 2014 ASCO Annual Meeting

  20. Results: BEV Treatment Impacted PFS in Proneural and Mesenchymal Subtypes Presented By Michael Prados at 2014 ASCO Annual Meeting

  21. Results: BEV Effect on OS was Evident Only in the Proneural Subtype Presented By Michael Prados at 2014 ASCO Annual Meeting

  22. Results: Effect of BEV on OS was Significant in Univariate and Multivariate Analyses Presented By Michael Prados at 2014 ASCO Annual Meeting

  23. Conclusions Presented By Michael Prados at 2014 ASCO Annual Meeting

More Related